Overview

Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study

Status:
Not yet recruiting

Trial end date:
2026-07-31

Target enrollment:

Participant gender:

Summary

This study is design to prospectively investigate the safety and efficacy of Fruquintinib combined with Serplulimab in first-line treatment of non-clear renal cell carcinoma. Fruquintinib, a vascular endothelial growth factor receptor inhibitor, is an anticancer drug independently developed in China to treat refractory metastatic colorectal cancer (mCRC). This is a Single-arm, multicenter, prospective phase 2 clinical study.

Phase:

Phase 2

Details

Lead Sponsor:

RenJi Hospital

Collaborator:

Shanghai Zhongshan Hospital